Multiple Intravenous Injections of Valproic Acid-Induced Mesenchymal Stem Cell from Human-Induced Pluripotent Stem Cells Improved Cardiac Function in an Acute Myocardial Infarction Rat Model

Shuyuan Guo,1 Yusen Zhang,2 Yanmin Zhang,3 Fanhua Meng,4 Minghua Li,3 Zhendong Yu,3 Yun Chen,2,5 and Guanghui Cui2

1Shantou University, School of Medicine, China
2Peking University Shenzhen Hospital, Ultrasound Department, China
3Peking University Shenzhen Hospital, Central Laboratory, China
4Peking University Shenzhen Hospital, Reproductive Medical Center, China
5Shenzhen Key Laboratory of Drug Addiction and Safe Medication, China

Correspondence should be addressed to Yun Chen; yunchen@sphmc.org and Guanghui Cui; cuiguanghui175@aliyun.com

Received 21 April 2020; Revised 10 November 2020; Accepted 2 December 2020; Published 17 December 2020

Academic Editor: Ruxana Sadikot

Copyright © 2020 Shuyuan Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mounting evidence indicates that the mesenchymal stem cell (MSC) injection is safe and efficacious for treating cardiomyopathy; however, there is limited information relating to multiple intravenous injections of human-induced pluripotent stem cell-derived mesenchymal stem cell (hiPSC-MSC) and long-term evaluation of the cardiac function. In the current study, MSC-like cells were derived from human-induced pluripotent stem cells through valproic acid (VPA) induction and continuous cell passages. The derived spindle-like cells expressed MSC-related markers, secreted angiogenic and immune-regulatory factors, and could be induced to experience chondrogenic and adipogenic differentiation. During the induction process, expression of epithelial-to-mesenchymal transition- (EMT-) related gene N-cadherin and vimentin was upregulated to a very high level, and the expression of pluripotency-related genes Sox2 and Oct4 was downregulated or remained unchanged, indicating that VPA initiated EMT by upregulating the expression of EMT promoting genes and downregulating that of pluripotency-related genes. Two and four intravenous hiPSC-MSC injections (10⁶ cells/per injections) were provided, respectively, to model rats one week after acute myocardial infarction (AMI). Cardiac function parameters were dynamically monitored during a 12-week period. Two and four-cell injections significantly improved left ventricular ejection fraction and left ventricular fractional shortening; four-injection markedly stimulated angiogenesis reduced the scar size and cell apoptosis number in the scar area in comparison with that of the untreated control model rats. Although the difference was insignificant, the hiPSC-MSC administration delayed the increase of left ventricular end-diastolic dimension to different extents compared with that of the PBS-injection control. No perceptible immune reaction symptom or hiPSC-MSC-induced tumour formation was found over 12 weeks. Compared with the PBS-injection control, four injections produced better outcome than two injections; as a result, at least four rounds of MSC injections were suggested for AMI treatment.

1. Introduction

Coronary artery disease is a major cause of morbidity and mortality worldwide. Despite recent achievements in acute myocardial infarction (AMI) treatment, the irreversible damage to cardiomyocytes after AMI leads to left ventricular (LV) remodeling and ischemic heart failure [1, 2]. Mesenchymal stem cells (MSCs) are mesoderm-derived cells with the capacity to differentiate into multicell lineages. MSCs exert an immune tolerant phenotype which is
Table 1: Primers used in quantitative real-time RT-PCR.

| Genes  | PCR primers                                                                 |
|--------|-----------------------------------------------------------------------------|
| E-cadherin | Sense primer: 5′-TTCTGCTGCTTGGTGGTTT-3′ |
|         | Antisense primer: 5′-TGGCTCAAGTGCAATCTCTG-3′                             |
| N-cadherin | Sense primer: 5′-CTCTGCGGCTGAAGGTTGC-3′                               |
|         | Antisense primer: 5′-CCAGGGCAGCCACCAAA-3′                               |
| Vimentin | Sense primer: 5′-GCCCTTAAAGGAAACATGA-3′                                 |
|         | Antisense primer: 5′-AGCTCTAGGCAAGTTC-3′                                 |
| Oct3/4  | Sense primer: 5′-GACAGGGGGAGGGAGGCTAGG-3′                                |
|         | Antisense primer: 5′-CTTCCCTCAGACGTTGCCCAAAAC-3′                          |
| Sox2    | Sense primer: 5′-GGGAAATGGGAGGGTTGC-3′                                   |
|         | Antisense primer: 5′-TTGCGGTAGGATGAGGGAATG-3′                            |
| GAPDH   | Sense primer: 5′-CATCAATGGAAATCCCATCA-3′                                 |
|         | Antisense primer: 5′-TTCTCCATGGTGTAAGAC-3′                               |

characterized by low level expression of MHC antigens and the lack of costimulatory molecules. Through releasing soluble immune modulators such as indoleamine 2, 3 dioxygenase (IDO), prostaglandin E2 (PGE-2), or nitric oxide (NO), MSCs suppress activation of immune cells [3].

In recent years, mesenchymal stem cell transplantation has emerged as a potential treatment means for ischemic heart disease [4–6]. In clinical trials, intracoronary delivery of bone marrow mononuclear cells or bone marrow MSCs has provided evidence of improved cardiac function, reduced scar area, and reduced prevalence of recurrent MI, stent thrombosis, and death [7–11]. Accumulating evidence has suggested that following AMI, chronic, excessive proinflammatory immune responses may account for progressive adverse remodeling and dysfunction of the myocardium, and the transplanted MSCs exert its therapeutic benefits by secreting factors to stimulate local angiogenesis and alleviate inflammatory activities [12–15].

To date, most experimental and clinical studies have used an intramyocardium or intracoronary delivery system. Intravenous cell delivery is advantageous for AMI treatment at a practical level, and multiple rounds of intravenous injections of MSCs are convenient and tolerable from the viewpoint of patients, whereas repeated intromyocardium or intracoronary cell delivery is not. However, numerous reports indicate that only a small portion of the injected cells could integrate into the infarct area after intravenous injections, while most of them are trapped in the lung, kidney, liver, and spleen, and are gradually cleared away in a period of time [16–18]. Even with the application of molecule targeting delivery systems, such as ICAM or SDF1/CXCR4, the retaining rate of the injected cells in the infracted area is still less than 30% [19, 20].

Ne’meth et al. demonstrated that the exogenous MSCs accumulated in the lung could transmigrate outside to the vascular space and rapidly interact with lung-resident tissue macrophages; stimulated by the MSCs, endogenous macrophages produce large amount of interleukin-10. Since this seminal report, there has been a plurality of reports validating a unique cross-talk between exogenous MSCs and recipient monocyte and/or macrophages as part of the anti-inflammatory effect of MSCs [21]. Completely curbing excessive and prolonged inflammation in myocardium by a single intravenous administration of MSCs is impossible; therefore, repeated infusions over time might exert superior, prolonged anti-inflammatory effects.

Despite the advantages of using MSCs derived from the bone marrow, adipose tissue, or umbilical cord for cell therapy, several issues incurred by properties of these cells limit their application in clinical use. For example, they are limited in number and quickly lose their differentiation potential during in vitro expansion [22]. As for autologous application, MSCs decline in quantity and quality with age, isolated MSCs are often composed of heterogeneous cell populations, and each population may have different proliferative and differentiation potential that make clinic application difficult [23, 24]. A large number of primitive MSCs can be isolated from the perinatal tissue, but it can be obtained from only around one-third of umbilical cord blood specimens, and the access to the abortal tissue requires ethical approval [25, 26].

The human induced pluripotent stem cell (hiPSC) is an attractive stem cell source for cell therapy. In comparison to isolation of primary cells, iPSCs can be harvested free of ethical constraints and offer a unified starting point for generation of standardised derivatives at large scale [27]. Thus, differentiating hiPSC into MSC (hiPSC-MSC) before transplantation is one of the most promising approaches for the safe and effective use of the induced pluripotent stem cells.

Before clinic application of the induced hiPSC-MSC, there are questions remaining to be answered. First, do the intravenous injected hiPSC-MSCs have tumor formation potential in the hosts? Second, will immune reaction to transplanted cells be initiated and accelerated by repeated injections of hiPSC-MSCs? Third, what is the optimal cell dosage for improving the cardiac function without causing fatal side effects?

Valproic acid (VPA), a histone deacetylase inhibitor (HDI), is used as a mood stabiliser and antiepileptic drug. Recently, it has been found that VPA treatment could modulate multipotency, migration, proliferation, and differentiation of cord blood and periodontal MSCs [28, 29].
Epithelial-to-mesenchymal transition (EMT) has been regarded as the first stage of mesoderm commitment in hESCs [30], and VPA plays an important role in the process of cell mesoderm commitment induction [31].

In this study, we hypothesised that MSC-like cells could be derived from human hiPSCs by VPA induction and planned to undertake two and four rounds of intravenous administration of the derived hiPSC-MSCs in a rat model of AMI. By doing so, we attempted to test the safety and the effectiveness of the derived MSC-like cells in treating AMI within a 12-week period.

2. Materials and Methods

2.1. Human-Induced Pluripotent Stem Cell Cultures. Human iPSC cell line PBMC-5 (derived from the peripheral blood
mononuclear cell of a 31-year-old Chinese Han female) was kindly provided by Dr Tiancheng Zhou at the Guangzhou Institute of Biomedicine & Health, Chinese Academy of Sciences, under the appropriate human ethics and material transfer agreements. hiPSCs were routinely grown as bulk cultures on a widely used commercially available defined medium, mTeSR1 (Stem Cell Technologies, Vancouver, BC, Canada), in combination with the cell attachment matrix Matrigel (BD Biosciences, San Diego, USA).

2.2. MSC Differentiation of hiPSC. hiPSC bulk cultures were seeded into the mTeSR1 medium on a Matrigel-coated six-well plate as large colonies at high confluence, and then the medium was changed to the MSC differentiation medium containing DMEM-Ham’s F-12 basal medium supplemented with 20% knockout serum replacement (KOSR), 1 mM L-glutamine, 10 mM nonessential amino acids, 50 U/mL penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA), and 0.5 mM VPA (Sigma-Aldrich, St. Louis, USA). The MSC differentiation medium was replaced every other day for eight days, and then the cells were passaged to a single cell suspension using the TrypLeSelect (Invitrogen). Single cells were seeded at a density of 40,000 cells per cm² into the MSC medium (DMEM high glucose basal medium supplemented with 10% foetal bovine serum, 1 mM L-glutamine, 50 U/mL penicillin/streptomycin, and 10 mM nonessential amino acids, all from Invitrogen) as the first passage, and then in the subsequent passages, 20,000 cells per cm² were seeded.

2.3. Quantitative Real-Time RT-PCR. Total RNA was isolated using the RNase mini kit (Qiagen, Valencia, CA, USA). A high-capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA, USA) was used to reverse transcribe 1 μg of RNA into cDNA with MMLV reverse transcriptase and random primers according to the manufacturer’s instructions (85°C, 5 s, and 37°C, 1 h). Real-time PCR was performed using specific primers under optimal reaction conditions (94°C, 30 s; 60°C, 35 s; 72°C, 40 s; 30 cycles) for quantification of the gene expression using SYBR-Green RT-PCR reagents (Applied Biosystems). The 2-ΔΔCq method was used to analyze relative gene expression level. Table 1 lists the primers used.

2.4. Detection of MSC Specific Markers by Flow Cytometry. Adherent spindle-like cells at the sixth passage were harvested by trypsinization. They were resuspended for measuring expression of typical MSC surface markers (CD29, CD44, CD73, CD90, and CD105) as well as markers of hematopoietic cell lineages (CD34, CD45, and human leukocyte antigen-DR isotype) by fluorescent-activated cell sorting (FACS). Fluorescent conjugated antibodies: anti-CD29, CD73, CD90, and CD105 (Biolegend, San Diego, CA, USA); anti-CD45, CD34, and HLA-DR (Boster, Wuhan, China). Isotype control antibodies were used as negative controls to optimize parameters during analyses using BD-FACScan (Becton Dickinson, Franklin Lakes, NJ, USA). Data were analyzed using FlowJo (Ashland, OR, USA).

2.5. Differentiation Assay of hiPSC-MSC. Induction of chondrogenic and adipogenic differentiation and subsequent staining of induced cells were conducted as described previously [32]. Chondrogenic differentiation was induced by culturing cells with a chondrogenic induction medium (DMEM supplemented with 10% FBS, 6.25 μg/mL of insulin, 50 nM of ascorbate phosphate, and 10 μg/mL of transforming growth factor-β) for two weeks. Formation of sulphated proteoglycans was visualised by Alcian Blue staining.

To induce adipocytic differentiation, cells were cultured as monolayers, allowing to become near confluent and then maintained in the adipogenic induction medium (DMEM supplemented with 10% FBS, 10−2 M of dexamethasone, and 10 μg/mL of insulin) for two weeks. Then, cells were assessed by Oil-Red-O staining as an indicator of intracellular lipid accumulation.

2.6. Cytokine Production Analysis. Two million umbilical cord derived MSCs (UC-MSCs) and hiPSC-MSCs were, respectively, seeded in a 10 cm diameter culture dish in the MSC medium for the purpose of comparing the cytokine production level between these two cell groups. After a three-day culture period, the supernatants were collected for detecting IGF, VEGF, HGF, IDO, PGE2, and IL-10 production. Cytokine concentration was measured using ELISA detection kits according to the manufacturer’s instructions (IGF and PGE2, Multi Science, Hangzhou, China; VEGF and HGF, Abcam, Cambridge, MA, USA; IDO, RayBio Norcross, GA, USA; IL-10, Sino Biological, Beijing, China). Samples were analyzed using a 1510 spectrophotometer (Thermo Fisher, Vantaa, Finland).

2.7. Animals and AMI Induction. Male Sprague–Dawley rats (4 weeks, body mass 230-270 g) were purchased from the Medical Experimental Animal Centre of Guangdong Province (Guangdong, China). They were housed in a room at constant temperature (20°C) and humidity (45%) on a 12-h light–dark cycle. Rats had free access to standard laboratory chow and tap water.
Approval for animal experimentation was obtained from the Ethics Committee of Peking University Shenzhen Hospital. Chinese laws relating to the care and treatment of animals were followed strictly throughout the study and complied with Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.

A left thoracotomy was undertaken between the fourth and fifth ribs of rats. A suture was constructed around the left anterior descending coronary artery (LADCA). Ischemia was maintained for 40 min, followed by reperfusion. In sham control rats, the constructed suture was immediately removed to restore blood flow.

2.8. Evaluation of the Cardiac Function by Echocardiography. The cardiac function was evaluated using a two-dimensional echocardiography system (Vevo 2100; Visual Sonics, Toronto, ON, Canada) with an MS250 transducer (13–24 MHz). We measured parameter changes pertaining to the left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), and left ventricular end-diastolic dimension (LVEDD).

2.9. Intravenous Administration of hiPSC-MSC in the Rat Model of AMI. One week after AMI, model rats were anaesthetised (40 mg/kg body mass of pentobarbital sodium), and the cardiac function was evaluated by echocardiography. Rats with LVEF lower than 55% were selected for this experiment and divided randomly into two hiPSC-MSC injection groups (two and four injections, \( n = 8 \)) and one phosphate-buffered saline (PBS) injection control group (\( n = 8 \)). Two
and four intravenous boli of $1 \times 10^6$ hiPSC-MSCs (passage 6) were given, respectively, to rats in the hiPSC-MSC-treated groups, and PBS was provided to rats in the control group. hiPSC-MSC intravenous injections were carried out once a week. The cardiac function was evaluated once every two weeks after the first infusion in the 12-week period.

2.10. Quantification of the Scar Size. Masson’s Trichrome staining was used to assess the area of myocardial scars 12 weeks after AMI induction. This procedure stains the viable area pink and the scar area blue. Briefly, three equal slices below the suture were fixed in 4% formaldehyde and embedded in paraaffin and cut into sections of thickness 5 μm. To detect fibrosis, the sections were stained with Masson’s Trichrome and assessed by a pathologist blind as to study protocol. The percentage of the scar area was quantified by a computerised morphometry system with a microscope (Olympus, Tokyo, Japan).

2.11. Vascularisation Evaluation in the Scar Area. Three frozen equal slices below the suture were fixed and blocked for immunohistochemical detection of the α-SMA expression. Primary mouse anti-rat α-SMA antibodies (Biolegend, San Diego, CA, USA), secondary biotin-coupled anti-mouse IgG antibody, and avidin-horseradish peroxidase conjugates (Boster, Wuhan, Hubei, China) were applied, respectively, following a standard immunohistochemistry procedure. Irrelevant antibody was used as a negative control. α-SMA+ cell capillary in the scar regions was counted by a high-power field (200×) in each section, and at least five randomly fields in each section were analyzed.

2.12. Cell Apoptosis Assay. The TdT-mediated dUTP nick-end labeling (TUNEL) assay was performed on heart sections according to the manufacturer’s recommendations (KeyGEN BioTECH, Nanjing, Jiangsu, China) to quantify cardiomyocyte apoptosis. Counterstaining with hematoxylin was conducted to visualize normal nuclei. Apoptotic cells were counted in 5 randomly selected high-power fields (400×) from the border and infarcted area of three sections from each heart and averaged.

2.13. Statistical Analyses. Data were shown as mean ± SD and analyzed using SPSS software, Version 11.0. One-way ANOVA with LSD- $t$ was used in multiple group comparisons, and $P < 0.05$ was considered significant.

3. Results

3.1. Morphology Transformation during hiPSC-MSC Induction. Without the presence of VPA, undifferentiated
hiPSCs cultured on Matrigel in the mTeSR1 medium appeared as dense, tightly packed cell colonies. Eight-day incubation with VPA drove more than 60% of hiPSCs to form a monolayer of larger cuboidal-shaped epithelial-like cells, leaving only small islands of undifferentiated cells.

From the second passage in the MSC medium, the morphology of differentiating cells gradually altered from larger cuboidal-shaped epithelial-like towards olive shape-like, and then on the sixth passage, more than 90% of the adherent cells maintained a small spindle-shaped morphology (Figure 1).

3.2. VPA Promoted the EMT-Related Gene Expression. To examine whether, or not, VPA could induce hiPSCs to mesoderm commitment, pluripotency-related transcription factors and EMT-related gene expression were evaluated at the fourth and eighth induction days. In comparison with DMSO-treated control hiPSCs, four-day VPA induction significantly upregulated the expression of the EMT-related gene N-cadherin and vimentin, and the upregulation was continued to day eight. The pluripotency-related transcription factor Sox2 was downregulated, while the Oct4 expression remained at a similar level. Unexpectedly, the EMT reverse process MET-related gene E-cadherin expression was upregulated (Figure 2).

In comparison with DMSO-treated control hiPSCs, four- to eight-day VPA treatment significantly upregulated the expression of the EMT-related gene N-cadherin and
vimentin, and the pluripotency-related transcription factor Sox2 was downregulated, while the Oct4 expression remained at a similar level. The EMT reverse process MET-related E-cadherin gene expression was upregulated at the same time.

3.3. Differentiation Induction and Surface Marker Expression of hiPSC-MSC. Cells at passage 6 were cultured with the chondrogenic differentiation medium for two weeks, and sulphated proteoglycans produced by cell plaques could be detected using Alcian Blue staining. When cells were cultured in the adipogenic induction medium, intercellular lipid vacuoles could be seen since day 10 by Oil-Red-O staining (Figure 3). More than 98% of passage 6 hiPSC-MSCs expressed typical MSC surface markers (CD29, CD44, CD73, CD90, and CD105), while the expression of markers of hematopoietic cell lineages (CD34, CD45, and HLA-DR) was below 0.4% (Figure 4).

More than 98% of passage 6 hiPSC-MSCs expressed typical MSC surface markers (CD29, CD44, CD73, CD90, and CD105), while the expression of markers of hematopoietic cell lineages (CD34, CD45, and HLA-DR) was below 0.4%.

3.4. hiPSC-MSC Produced Angiogenesis and Immune Regulatory Factors. Angiogenic and immune regulatory factor secretion level of hiPSC-MSCs was compared with that of UC-MSCs. UC-MSCs expressed IGF, VEGF, HGF, IDO, PGE2, and IL-10. The expression level of IGF, VEGF, HGF, IDO, PGE2, and IL-10 of hiPSC-MSCs did not significantly differ from that of UC-MSCs, but the HGF expression level of hiPSC-MSCs was significantly lower compared with that of UC-MSCs, **P < 0.001 (Figure 5).

The expression level of VEGF, IGF, IDO, PGE2, and IL-10 of hiPSC-MSCs was not significantly different from that of UC-MSCs; however, the HGF expression level of hiPSC-MSCs was significantly lower compared with that of UC-MSCs, ***P < 0.001.

3.5. hiPSC-MSC Dosages and Adverse Effects. In our preliminary experiment, severe dyspnea was found in some rats immediately after intravenous infusions of 2 × 3 × 10⁶ hiPSC-MSCs, and these rats died quickly (>30-50%), perhaps due to thromboemboli in the lungs formed by hiPSC-MSCs, as reported by other researchers [16, 17, 33]. As a result, we reduced the dose of each injection to 1 × 10⁶ cells as reported by other researchers [16, 17, 33]. As a result, we reduced the dose of each injection to 1 × 10⁶ hiPSC-MSCs to model rats and the whole 12-week period, symptoms relating to acute or chronic immunoreactions, such as dyspnea, convulsion, oedema, skin rash, langour, or progressive emaciation, were monitored: no perceptible symptoms were found. At the end of the twelfth week, anatomical examination of the model rats was undertaken, and no tumor formation or evident pathological changes were identified.

3.6. hiPSC-MSC Administrations Improved the Cardiac Function. Cardiac function improvement was analyzed by monitoring LVEF obtained at week 0 (the day on which the first hiPSC-MSC injection was given) and weeks 2, 4, 6, 8, 10, and 12. From week 0 to week 12 before sacrificing the rats, LVEF of the sham group kept unchanged; in the PBS-injection group, LVEF continued to decline, from 48.36 ± 7.30% to 36.94 ± 8.31%; in the two-injection group, LVEF increased from 47.44 ± 7.6% at week 0 to 57.9 ± 4.8% at week 12; in the four-injection group, LVEF grew from 46.67 ± 4.4% at week 0 to 64.7 ± 2.4% at week 12 (Figure 6(a)). Significant differences were found when comparing MSC-injection groups with the PBS-injection group at the end of 12 weeks (PBS-injection group v. two-injection group, *P < 0.001; PBS group v. four-injection group, *P < 0.001). There was a significant difference between the two-injection group and the four-injection group, **P < 0.05 (Figure 6(b) and Table 2).

LVFS is an important indicator for evaluating the LV systolic function. From week 0 to week 12, LVFS of the sham group kept stable; in the PBS-injection group, LVFS declined

### Table 2: Statistical analysis of LVEF at the end of 12 weeks.

|               | LVEF    | P value |
|---------------|---------|---------|
| PBS-injection | 36.94 ± 8.31% | P < 0.001 |
| Two-injection | 57.9 ± 4.8%   |         |
| PBS-injection | 36.94 ± 8.31% | P < 0.001 |
| Four-injection| 64.7 ± 2.4%   | P < 0.05  |
| Two-injection | 57.9 ± 4.8%   |         |
| Four-injection| 64.7 ± 2.4%   |         |

### Table 3: Statistical analysis of LVFS at the end of 12 weeks.

|               | LVFS    | P value |
|---------------|---------|---------|
| PBS-injection | 19.75 ± 3.8% | P < 0.001 |
| Two-injection | 30.67 ± 3.7% |         |
| PBS-injection | 19.75 ± 3.8% | P < 0.001 |
| Four-injection| 34.25 ± 5.4% |         |
| Two-injection | 30.67 ± 3.7% |         |
| Four-injection| 34.25 ± 5.4% | P > 0.05 |

### Table 4: Statistical analysis of LVEDD at the end of 12 weeks.

|               | LVEDD(mm) | P value |
|---------------|-----------|---------|
| PBS-injection | 9.36 ± 0.77 | P > 0.05 |
| Two-injection | 8.67 ± 0.86 |         |
| PBS-injection | 9.36 ± 0.77 | P > 0.05 |
| Four-injection| 8.02 ± 0.34 |         |
| Two-injection | 8.67 ± 0.86 |         |
| Four-injection| 8.02 ± 0.34 | P > 0.05 |
from 25.12 ± 2.53% at week 0 to 19.75 ± 3.8% at week 12; in
the two-injection group, LVFS increased from 27.64 ± 2.34% at
week 0 to 30.67 ± 3.7% at week 12; in the four-injection
group, LVFS ascended from 27.97 ± 2.34% at week 0 to
34.25 ± 5.4% at week 12 (Figure 6(c)). Significant differences
were observed upon comparison of the PBS-injection group
with the MSC-injection groups at week 12 (PBS-injection
group v. two-injection group, \( P < 0.001 \); PBS-injection group
v. four-injection group, \( P < 0.001 \)), and there was no significant
difference between the four-injection group and the
two-injection group (Figure 6(d) and Table 3).

LVEDD was measured continuously after two to four
rounds of hiPSC-MSC infusions over 12 weeks. In the sham
group, no significant variation of LVEDD was found; in the
PBS-injection group, LVEDD continued to increase from
7.8 ± 0.71 mm at week 0 to 9.36 ± 0.77 mm at week 12. In
the MSC-injection groups, cell treatment prevented LVEDD
increase to different extents from week 0 to week 12 com-
pared with the PBS-injection group (two-injection group:
from 7.65 ± 0.69 mm to 8.67 ± 0.86 mm; four-injection
group: from 7.5 ± 0.52 mm to 8.02 ± 0.34 mm) (Figure 6(e)),
despite the insignificant differences among these groups (Figure 6(f) and Table 4).

3.7. hiPSC-MSC Administration Reduced the Scar Size. To
analyze the potential effect of hiPSC-MSC therapy on the
scar size in the AMI model, we stained sections of the scar
area with Masson’s trichrome. Twelve weeks after AMI, his-
tology showed that scar tissue formation in the infarct area
was composed mainly of the fibrotic tissue with some inflam-
matory cells, and the scar tissue was stained blue, and the vi-
able area was pink (Figure 7(a)): PBS-injection group,
13.74 ± 3.4%; two-injection group, 10.18 ± 2.16%; and four-
injection group, 7.08 ± 3.68%. MSC treatments reduced the
scar area in the cell-injection groups compared with those
in the PBS-injection group, and there was a significant
difference in the four-injection group, \( P < 0.01 \) (Figure 7(b)
and Table 5).

3.8. hiPSC-MSC Administrations Promoted Vascularisation
in the Scar Area. Using anti-α-SMA antibody staining, we
found that injections of hiPSC-MSC increased the number
of α-SMA+ artery vessels in the scar area of the MSC-
injection groups compared with that of the PBS-injection
group (PBS-injection group: 6.12 ± 1.24 v. two-injection
group: 8.625 ± 1.06, \( P < 0.05 \); PBS-injection group: 6.12 ±
1.24 v. four-injection group: 13.62 ± 2.19, \( P < 0.001 \)). There
was a significant difference when comparing two- and four-
injection groups, \( P < 0.001 \) (Figure 8 and Table 6).

3.9. hiPSC-MSC Administrations Reduced Apoptotic Cell
Number in the Border and Infarcted Area. Representative
TUNEL staining images (cells with brown stain) of the
four groups are shown, respectively, in Figure 9a. The
results indicated that the cell number of apoptosis in the
border and infarcted area was reduced in the four- and
two-injection groups (74.53 ± 7.42 and 97.33 ± 8 cells/hpf )
compared with that of the PBS-injection control group
(129.33 ± 33.61 cells/hpf), and significant reduction could
be found in the comparison between the four-injection
group and the PBS-injection group, \( **P < 0.01 \) (Figure 9b
and Table 7).

| Scar size   | \( P \) value |
|-------------|--------------|
| PBS-injection | 13.74 ± 3.4% | \( P > 0.05 \) |
| Two-injection | 10.18 ± 2.16% | \( P < 0.01 \) |
| PBS-injection | 13.74 ± 3.4% | \( P < 0.01 \) |
| Four- injection | 7.08 ± 3.68% | \( P > 0.05 \) |
| Two- injection | 10.18 ± 2.16% | \( P < 0.01 \) |
| Four- injection | 7.08 ± 3.68% | \( P < 0.01 \) |

Figure 7: hiPSC-MSC administration reduced the scar area. (a) Masson’s Trichrome staining, scar tissue was stained blue, and the viable area
was pink. A. Normal heart. B. Sham infarcted heart. C. PBS-injection-treated AMI heart. D. Two-injection-treated AMI heart. E. Four-
injection-treated AMI heart. (b) MSC treatments reduced the scar area in the cell-injection groups compared with those in the PBS-
injection group, and there was significant difference in the four-injection group, \( **P < 0.01 \).
**4. Discussion**

MSC infusions have been investigated as a treatment means for cardiac disease for more than a decade. Although accumulating evidence suggests that the MSC infusion can improve the cardiac function [34], however, information on the long-term dynamic outcomes of multiple hiPSC-MSC infusions on cardiac disease is unavailable.

The current study is based on the concept that a persistent, excessive inflammatory response contributes to progressive myocardial dysfunction post-AMI, and the chronic inflammatory response cannot be suppressed permanently by a single infusion of MSCs.

Human-induced pluripotent stem cells are an attractive stem cell source for cell therapy. Spontaneous mesoderm commitment of hiPSCs can be initiated by manually dissociation and followed by subsequent passaging or embryoid body formation. It usually takes more than 30 days to generate cells with increased MSC marker expression and bilineage mesenchymal differentiation potential from hiPSCs [27, 35–37]. Small molecules, such as SB431542 and VPA, play an impotent role in epithelial-to-mesenchymal transition induction [27, 31], and SB431542 is reported to be feasible in MSC derivation from hiPSCs, but it still takes more than twenty days to generate MSC-like cells [27].

Through modifying histone acetylation, VPA greatly accelerated the EMT process of hiPSC, and large number of MSC like cells could be obtained within 15 days in our research. Compared with the spontaneous commitment and SB431542 induction method, the VPA treatment method of obtaining MSC is effective and timesaving. The derived cells expressed MSC-related marker, secreted angiogenic and immune regulatory factors in levels comparable to that of UC-MSCs, except for HGF, and could be induced to experience chondrogenic and adipogenic differentiation, and more importantly did not form a tumor in vivo.

During the induction process, the expression of EMT-related genes N-cadherin and vimentin was upregulated to a very high level, and the expression of pluripotency-related genes Sox2 and Oct4 was downregulated or remained unchanged, indicating that VPA initiated the process of EMT through upregulating EMT-promoting genes and downregulating pluripotency-related gene expression. Although the EMT opposite process MET-related gene E-cadherin expression was upregulated for unspecified reasons, under the very high level expression of N-cadherin and vimentin, the upregulated E-cadherin expression could not prevent the initiation of EMT in the VPA-treated cells.

It has been reported that VPA might activate and stabilize neurons and astrocytes by stimulating the expression of trophic factors, and recent reports indicate that VPA treatment could enhance multipotency, migration, proliferation, and differentiation of MSCs [28, 29]. In our research, we found that low concentration (0.1-0.5 mM) of VPA could

---

**Table 6: Statistical analysis of angiogenesis at the end of 12 weeks.**

|          | α-SMA⁺ artery number/hpf | P value |
|----------|--------------------------|---------|
| PBS-injection | 6.12 ± 1.24             | P < 0.05|
| Two-injection | 8.625 ± 1.06            |         |
| PBS-injection | 6.12 ± 1.24             | P < 0.001|
| Four-injection | 13.62 ± 2.19            |         |
| Two-injection | 8.625 ± 1.06            | P < 0.001|
| Four-injection | 13.62 ± 2.19            |         |
increase MSC viability, whereas concentrations that exceed 0.5 mM would inhibit cell proliferation and induce cell apoptosis in a dosage-dependent manner (data not shown) indicating its bifunctional property.

Since VPA initiate EMT through modifying histone acetylation (epigenetic alteration), we did not perform karyotype analysis on these hiPSC-induced MSCs, and tumor formation monitoring only lasted twelve weeks; hence, we do not know whether the injected cells would form tumor in a longer period.

Tissue origin greatly affects stem cell differentiation and function of the derived cells. The tissue-specific epigenetic profiles, such as DNA methylation (DNAm) patterns, may not be erased and reestablished completely during reprogramming of somatic cells into hiPSCs. This specific characteristic also remains upon redifferentiation into hiPSC-MSCs [38]. The low-level secretion of HGF in hiPSC-MSC may be related to the incomplete erasing of DNA methylation pattern during the reprogramming process.

Intravenous infusions of hiPSC-MSCs to rats were started one week after AMI induction and continued for the following two to six weeks, because evidence suggests that application of MSCs seven days after AMI is preferable to that given one day after AMI due to differences in the cardiac environment after AMI [16]. During the four rounds of infusions of $1 \times 10^{6}$ hiPSC-MSCs to rats, no perceptible adverse effect and hiPSC-MSC-induced tumor formation were found over 12 weeks.

LVEF and LVFS are the most commonly used parameters for evaluating cardiac performance in clinical practice. LV functional deterioration following AMI remains incomplete after a few days [39]. LVEDD is a predictor of ventricular remodeling [40]. The pathophysiological changes of ventricular remodeling can be divided into early and late phases after AMI onset. The early phase involves expansion of the infarct area, and late remodeling involves time-dependent dilatation, distortion of ventricular shape, and mural hypertrophy [41].

We demonstrated that, after AMI induction, without intervention, the LVEF, LVFS, and LVEDD of the PBS-injection control group continued to deteriorate over 12 weeks. hiPSC-MSC treatment improved LVEF and LVFS and delayed the increase of LVEDD in the cell-treated groups. LVEDD increases among differently treated groups were insignificant within a 12-week period, perhaps due to ventricular remodeling being a chronic process.

The reasons for the poorer improvement of the cardiac function in the two-injection group may be because, without continuous provision of hiPSC-MSCs to model rats, the beneficial factors secreted by the hiPSC-MSCs were exhausted two to three weeks after the second cell injection; thus, the uncurbed inflammation continued for a period of time. With
a short lifespan, the injected hiPSC-MSCs could not survive or multiply for more than three weeks [25, 26]. In addition, the infused heterogenic hiPSC-MSCs could have been cleared gradually by a system of phagocytosis, although it is known that heterologous MSCs can evade the immune system. This phenomenon emphasises the importance of multiple rounds of MSC infusions on sustaining cardiac function improvement.

Van Dijk and Sheu et al. showed that injections of adipose tissue-derived MSCs could promote angiogenesis and reduce the scar area significantly after AMI [16, 42]. In our experiment, the apoptotic cell number of the cell-treated groups was reduced; the total α-SMA⁺ artery number in the scar area in the cell-treated groups was increased, and the size of this area was shrunk significantly compared with that in the control group. These results are consistent with that of Van Dijk and Sheu et al., indicating that the increased angiogenesis played an important role in reducing the scar area and improving the cardiac function.

In conclusion, we demonstrated that MSC-like cells could be effectively induced from hiPSCs by simple VPA treatment, and multiple intravenous infusions of hiPSC-MSCs to AMI rats were an efficacious and safe measure, whereby to restore reduced cardiac function.

Data Availability
All the data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors declare that they have no competing interests with any individual or institution.

Authors’ Contributions
Shuyuan Guo and Yusen Zhang contributed equally to this work.

Acknowledgments
We thank Dr. Tiancheng Zhou at Guangzhou Institute of Biomedicine & Health, Chinese Academy of Sciences for kindly providing the human iPSC cell line (PBMC-5). This work was supported by the Shenzhen Science and Technology Innovation Committee [grant number: JCYJ20180507183224565 and JCYJ20170816105345191] and National Natural Science Foundation of China [grant number: 81871358].

References
[1] C. Toma, M. F. Pittenger, K. S. Cahill, B. J. Byrne, and P. D. Kessler, "Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart," Circulation, vol. 105, no. 1, pp. 93–98, 2002.
[2] R. W. Yeh, S. Sidney, M. Chandra, M. Sorel, J. V. Selby, and A. S. Go, "Population trends in the incidence and outcomes of acute myocardial infarction," The New England Journal of Medicine, vol. 362, no. 23, pp. 2155–2165, 2010.
[3] A. Gebler, O. Zabel, and B. Seliger, "The immunomodulatory capacity of mesenchymal stem cells," Trends in Molecular Medicine, vol. 18, no. 2, pp. 128–134, 2012.
[4] D. C. Vela, G. V. Silva, J. A. Assad et al., "Histopathological study of healing after allogeneic mesenchymal stem cell delivery in myocardial infarction in dogs," The Journal of Histochemistry and Cytochemistry, vol. 57, pp. 167–176, 2008.
[5] E. C. Perin, M. Tian, F. C. Marini et al., "Imaging long-term fate of intramyocardially implanted mesenchymal stem cells in a porcine myocardial infarction model," PLoS One, vol. 6, no. 9, p. e22949, 2011.
[6] A. R. Williams and J. M. Hare, "Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease," Circulation Research, vol. 109, pp. 923–940, 2011.
[7] S. L. Chen, W. W. Fang, F. Ye et al., "Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction," The American Journal of Cardiology, vol. 94, no. 1, pp. 92–95, 2004.
[8] V. Schächinger, S. Erbs, A. Elsässer et al., "Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction," The New England Journal of Medicine, vol. 355, no. 12, pp. 1210–1221, 2006.
[9] G. P. Meyer, K. C. Wollert, J. Lotz et al., "Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (bone marrow transfer to enhance ST-elevation infarct regeneration) trial," Circulation, vol. 113, no. 10, pp. 1287–1294, 2006.
[10] J. M. Hare, J. H. Traverse, T. D. Henry et al., "A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction," The American Journal of Cardiology, vol. 54, pp. 2277–2286, 2009.
[11] V. Jeevanantham, M. Butler, A. Saad, A. Abdel-Latif, E. K. Zuba-Surma, and B. Dawn, "Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters a systematic review and meta-analysis," Circulation, vol. 126, no. 5, pp. 551–568, 2012.
[12] T. Kinnaird, E. Stabile, M. S. Burnett, and S. E. Epstein, "Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences," Circulation Research, vol. 95, no. 4, pp. 354–363, 2004.
[13] T. Kinnaird, E. Stabile, M. S. Burnett et al., "Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms," Circulation Research, vol. 94, no. 5, pp. 678–685, 2004.
[14] F. van den Akker, S. C. A. de Jager, and J. P. G. Sluijter, "Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors," Mediators of Inflammation, vol. 2013, Article ID 181020, 13 pages, 2013.
[15] D. Kyurkchiev, I. Bochev, E. Ivanova-Todorova et al., "Secretion of immunoregulatory cytokines by mesenchymal stem cells," World Journal of Stem Cells, vol. 6, no. 5, pp. 552–570, 2014.
S. Y. Um, H. Lee, Q. Zhang, H. Y. Kim, J. H. Lee, and B. M. Seo, “Reduction of infarct size by intravenous injection of uncultured adipose derived stromal cells in a rat model is dependent on the time point of application,” Stem Cell Research, vol. 7, no. 3, pp. 219–229, 2011.

T. Måkelä, R. Takalo, O. Arvola et al., “Safety and biodistribution study of bone marrow-derived mesenchymal stromal cell and mononuclear cells and the impact of the administration route in an intact porcine model,” Cytotherapy, vol. 17, no. 4, pp. 392–402, 2015.

A. Sanetti, M. Grata, E. E. Efting, R. Panday, F. S. Villanueva, and C. Toma, “Suspension-expansion of bone marrow results in small mesenchymal stem cells exhibiting increased transpulmonary passage following intravenous administration,” Tissue Engineering, Part C, Methods, vol. 21, no. 7, pp. 683–692, 2015.

J. Galipeau and L. Sensébé, “Mesenchymal stromal cells: clinical challenges and therapeutic opportunities,” Cell Stem Cell, vol. 22, no. 6, pp. 824–833, 2018.

X. Q. Tian, Y. J. Yang, Q. Li et al., “Combined therapy with atorvastatin and atorvastatin-pretreated mesenchymal stem cells enhances cardiac performance after acute myocardial infarction by activating SDF-1/CXCR4 axis,” American Journal of Translational Research, vol. 11, no. 7, pp. 4214–4231, 2019.

L. Woudstra, P. A. J. Krijnen, S. J. P. Bogaards et al., “Development of a new therapeutic technique to direct stem cells to the infarcted heart using targeted microbubbles: StemBells,” Stem Cell Research, vol. 17, no. 1, pp. 6–15, 2016.

S. Fickert, U. Schröter-Bosbin, A. F. Groß et al., “Human mesenchymal stem cell proliferation and osteogenic differentiation during long-term ex vivo cultivation is not age dependent,” Journal of Bone and Mineral Metabolism, vol. 29, no. 2, pp. 224–235, 2011.

A. Stolzing, E. Jones, D. McGonagle, and A. Scutt, “Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies,” Mechanisms of Ageing and Development, vol. 129, no. 3, pp. 163–173, 2008.

S. Zhou, J. S. Greenberger, M. W. Epperly et al., “Age-related intrinsic changes in human bone marrow-derived mesenchymal stem cells and their differentiation to osteoblasts,” Aging Cell, vol. 7, no. 3, pp. 335–343, 2008.

S. Kern, H. Eichler, J. Stoeye, H. Klüter, and K. Bieback, “Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue,” Stem Cells, vol. 24, no. 5, pp. 1294–1301, 2006.

K. Bieback, S. Kern, A. Kocaoemer, K. Ferlik, and P. Bugert, “Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood,” Bio-medical Materials and Engineering, vol. 18, pp. 71–76, 2008.

Y. S. Chen, R. A. Pelekanos, R. L. Ellis, R. Horne, E. J. Woltzang, and N. M. Fisk, “Small molecule mesengetic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells,” Stem Cells Translational Medicine, vol. 1, no. 2, pp. 83–95, 2012.

S. Y. Um, H. Lee, Q. Zhang, H. Y. Kim, J. H. Lee, and B. M. Seo, “Valproic acid modulates the multipotency in periodontal ligament stem cells via p53-mediated cell cycle,” Tissue Engineering and Regenerative Medicine, vol. 14, no. 2, pp. 153–162, 2017.

L. A. Marquez-Curtis, Y. Qiu, A. Xu, and A. Janowska-Wieczorek, “Migration, proliferation, and differentiation of cord blood mesenchymal stromal cells treated with histone deacetylase inhibitor valproic acid,” Stem Cells International, vol. 2014, Article ID 610495, 14 pages, 2014.

J. Xu, S. Lamouille, and R. Derynck, “TGF-β-induced epithelial to mesenchymal transition,” Cell Research, vol. 19, no. 2, pp. 156–172, 2009.

Y. M. Zhang, Y. S. Zhang, M. H. Li et al., “Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acid-induced epithelial-mesenchymal transition and stemness in Hela, 5637 and SCC-15 cells,” Oncology Reports, vol. 41, no. 6, pp. 3545–3554, 2019.

G. H. Cui, Z. Qi, X. Guo, J. Qin, Y. Gui, and Z. Cai, “Rat bone marrow derived mesenchymal progenitor cells support mouse ES cell growth and germ-like cell differentiation,” Cell Biology International, vol. 33, no. 3, pp. 434–441, 2009.

D. Furlani, M. Ugurlucan, L. L. Ong et al., “Is the intravascular administration of mesenchymal stem cells safe: Mesenchymal stem cells and intravital microscopy,” Microvascular Research, vol. 77, no. 3, pp. 370–376, 2009.

B. Vrtovec and R. Bolli, “Potential strategies for clinical translation of repeated cell therapy,” Circulation Research, vol. 124, no. 5, pp. 690–692, 2019.

C. Xu, J. Jiang, V. Sottile, J. McWhir, J. Lebkowski, and M. K. Carpenter, “Immortalized fibroblast-like cells derived from human embryonic stem cells support undifferentiated cell growth,” Stem Cells, vol. 22, no. 6, pp. 972–980, 2004.

N. S. Hwang, S. Varghese, H. J. Lee et al., “In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells,” Proceedings of the National Academy of Sciences, vol. 105, no. 52, pp. 20641–20646, 2008.

S. E. Brown, W. Tong, and P. H. Krebsbach, “The derivation of mesenchymal stem cells from human embryonic stem cells,” Cells, Tissues, Organs, vol. 189, no. 1–4, pp. 256–260, 2008.

J. Frobel, H. Hemeda, M. Lenz et al., “Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells,” Stem Cell Reports, vol. 3, no. 3, pp. 414–422, 2014.

M. A. Konstam, J. E. Udelson, I. S. Anand, and J. N. Cohn, “Ventricular remodeling in heart failure: a credible surrogate endpoint,” Journal of Cardiac Failure, vol. 9, no. 5, pp. 350–353, 2003.

M. A. Konstam, D. G. Kramer, A. R. Patel, M. S. Maron, and J. E. Udelson, “Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment,” JACC: Cardiovascular Imaging, vol. 4, no. 1, pp. 98–108, 2011.

Y. Inaba, B. P. Davidson, S. Kim et al., “Echocardiographic evaluation of the effects of stem cell therapy on perfusion and function in ischemic cardiomyopathy,” Journal of the American Society of Echocardiography, vol. 27, no. 2, pp. 192–199, 2014.

J. J. Sheu, M. S. Lee, C. G. Wallace et al., “Therapeutic effects of adipose derived fresh stromal vascular fraction-containing stem cells versus cultured adipose derived mesenchymal stem cells on rescuing heart function in rat after acute myocardial infarction,” American Journal of Translational Research, vol. 11, no. 1, pp. 67–86, 2019.